Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Oncology
; 99(12): 756-765, 2021.
Article
in En
| MEDLINE
| ID: mdl-34518483
ABSTRACT
Background & Aims:
Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS:
We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were classified into 2 groups a group in which MTAs were administered to patients whose condition was refractory to TACE (n = 65) and a group in which MTAs were not administered (n = 65) at intermediate-stage HCC after propensity score matching (PSM). Time to stage progression (TTSP) and overall survival (OS) were calculated using the Kaplan-Meier method and analyzed using a log-rank test after PSM.RESULTS:
TTSP and OS of the group with MTA administration were significantly longer than those of the group without MTA administration (TTSP 36.4 vs. 17.9 months, p < 0.001; median survival time [MST] 44.6 vs. 26.6 months, p = 0.001). Within the up-to-seven criteria and administration of MTAs at the intermediate-stage HCC were identified as independent factors for TTSP and OS in the multivariate analysis. TTSP and OS in the era of the multi-MTA group were significantly longer than those in the era of the mono-MTA group (TTSP 44.8 vs. 27.4 months, p = 0.01; MST 53.4 vs. 33.3 months, p = 0.01).CONCLUSION:
The administration of MTAs in patients with intermediate-stage HCC contributes to the prevention of stage progression and prolongs OS.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylurea Compounds
/
Quinolines
/
Chemoembolization, Therapeutic
/
Carcinoma, Hepatocellular
/
Disease Progression
/
Sorafenib
/
Liver Neoplasms
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Oncology
Year:
2021
Document type:
Article
Affiliation country:
Japan